Oral Minoxidil for Lichen Planopilaris: The Add-On Trial

Lichen planopilaris (LPP) can destroy hair follicles and replace them with scar tissue. Treatment aims to preserve remaining hair and relieve symptoms. A prescription intended to thicken surviving hair needs to be judged separately from treatment intended to stop further follicle damage.¹²

That distinction matters when oral minoxidil is suggested. Ask which part of your plan addresses active inflammation and which part addresses hair appearance.

What the add-on study tested

A 2025 randomized trial³ enrolled 37 adults, including 24 women, with severe or treatment-resistant lichen planopilaris. Thirty completed six months. Both groups received methotrexate, folic acid and topical clobetasol; one also received oral minoxidil 1 mg daily.³

Disease activity improved in both groups, but the between-group comparison did not show a significant minoxidil advantage (P = 0.976). Masked dermatologists also assessed standardized photographs and magnified scalp images: hair-density and thickness ratings did not differ significantly between groups.³

The authors described regrowth in two minoxidil recipients in areas they called scarred. Two observations cannot establish restoration of destroyed follicles.³

This small trial tested one dose alongside particular medicines. It cannot settle every dose, longer treatment or use for coexisting female-pattern thinning. Five of 19 minoxidil recipients developed increased facial or limb hair.³

Why specialists may still discuss minoxidil

The 2026 EADV position statement describes low-dose oral minoxidil as an option alongside other LPP treatments to improve hair thickness. It draws on limited studies and expert interpretation. That is not a promise that the randomized trial showed an added benefit.²

Its discussion includes a retrospective series of 51 patients, treated for an average of 21 months. Subjective hair-density or hair-mass assessments showed 39% improvement, 53% stability and 8% worsening. Without a randomized comparison, those observations cannot establish how much change minoxidil caused. They also differ from masked photographic ratings in a six-month trial.²

Ask the dermatologist whether you have thinning outside the scarred patches that minoxidil might address. A fuller-looking part, reduced burning and a stable boundary of hair loss are different findings; one should not stand in for the others.

Agree on separate measures at follow-up

For diagnosed LPP, ask the clinic to record:

• Activity: itching, burning or pain, inflammation around follicles and evidence of spreading.
• Appearance: photographs or scalp measurements taken in comparable positions and lighting.
• Tolerability: new facial or body hair, dizziness, swelling or heartbeat symptoms after a medicine change.

These questions combine the condition’s symptoms with the outcomes and safety observations used in the study.¹³

The position statement recommends clinical review generally every 1 to 3 months, adjusted to the individual plan. An appearance check months later should not postpone assessment of new pain, inflammation or spreading.²

Review the tablet’s risks before starting

In the US, oral minoxidil is labeled for severe hypertension that has not responded adequately to other treatment. Hair-loss prescribing is off-label. Its boxed warning includes fluid around the heart and worsening angina; the label also warns about fluid retention and increased heart rate. Those warnings come from its blood-pressure use and do not provide an incidence estimate for this study’s 1 mg regimen.⁴

Review your blood pressure, heart and kidney history, and other medicines with the prescriber. Obtain instructions for monitoring and for symptoms that require contact. The patient information advises prompt contact for rapid weight gain, swelling, a faster heartbeat, chest pain or breathing difficulty. Severe chest pain or difficulty breathing warrants emergency assessment.⁴

Hair, Everywhere, Chapter 5’s “Your Hair Log,” includes dated photographs and treatment start dates. The book also flags scarring changes for prompt assessment. Use its recording method alongside dermatology follow-up; its six-month advice for ordinary shedding is not a reason to wait with suspected LPP.